Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
5 day chart consolidation ends at close of trading, couple that with a big update let’s see it fly from there , biotech is a place investors willing look to be unaffected by vax mandate ruling l, even if in foreign countries
After hours and Tomorrow big chance for news here imo
GRAY float still only 21mm so should be a non-issue..
Short interest is highest in history..
GLTA
When they announce funding for their research I think, maybe on January 23 when the 3 month chart consolidates, but the funding could be dilutive
GRAY with new all time lows AGAIN today...
When will GRAY turn
GRAY day. The sun'l come out tomorrow...
???
GLTA
January 5, no PR, not good, gotta be excited about the new year if you are a CEO
Low float, cup and handle to 12.65 possible, no toxic financing, big year here Vision ‘22
Share Structure
Market Cap Market Cap
41,146,896
01/03/2022
Authorized Shares
Not Available
Outstanding Shares
21,319,635
11/08/2021
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
Not Available
This is the day V for vision big story big year begins now
GRAY lets go !
GLTA
Funding announcement this week, V for Vision
Announcement soon cup and handle big potential vision V 22
V for vision?
22 is V
GRAY manipulated down with such Low-volume since July.
GRAY with crazy Low 21m Float has 200% pops when volume hits.
It's about time GRAY...
GLTA
...
...
.....
Funding not yet located for next phase of research, starting to remind me of sphs
Next chart opportunity January 3 6 month consolidation completes
GRAY's "cup" just spilled out...
What the heck?
STOP selling GRAY !
GLTA
Thanks SL. We've seen GRAY do it before with this low float so...
GLTA
Looking for a completion of cup and handle to 12.44 minimum on this run, consolidations are over on one and three month chart, SP surge can happen any day, great SS as well, CEO converted to some common stock today but not much, just 5000 shares. Looking good here.
Share Structure
Market Cap Market Cap
47,251,981
12/07/2021
Authorized Shares
Not Available
Outstanding Shares
21,319,635
11/08/2021
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
Not Available
https://www.otcmarkets.com/stock/GRAY/security
There is some short interest here too. Numbers are improving for this company.
“ 4:13p ET 11/11/2021 - Benzinga
Graybug Vision Q3 EPS $(0.38) Up From $(2.52) YoY
Graybug Vision (NASDAQ: GRAY) reported quarterly losses of $(0.38) per share. This is a 84.92 percent increase over losses of $(2.52) per share from the same period last year.Graybug Vision (NASDAQ:GRAY) reported quarterly losses of $(0.38) per share. This is a 84.92 percent increase over losses of $(2.52) per share from the same period last year.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
GRAY earnings today 11/11, and presenting tomorrow 11/12:
"Graybug Vision To Participate In The American Academy Of Ophthalmology 2021 Annual Meeting Nov. 12-15"
"Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two clinical data presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be held on November 12-15, 2021 in New Orleans, Louisiana, as well as a company presentation at the Eyecelerator@AAO 2021 event on November 11, 2021:
-- Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, to present company overview as part of Retina Showcase at Eyecelerator@AAO 2021 on November 11, 2021, at 2:50 p.m. ET / 1:50 p.m. CT / 11:50 a.m. PT, followed by a panel discussion.
-- Arshad Khanani, MD, MA, to present scientific E-Poster titled "Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2b Trial)". AAO attendees will be able to view E-Poster any time the Exhibit Hall is open from November 12-15. E-Poster will be available for viewing on AAO website after the Annual Session.
-- Veeral Sheth, MD, to present late breaker titled "Intravitreal Sunitinib Malate Depot (GB-102): Durability and Safety in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B)" at AAO Retina Subspecialty Day on November 13, 2021, at 10:02 a.m. ET / 9:02 a.m. CT / 7:02 a.m. PT."
GLTA
..
..
GRAY volume so low - they manipulate all they want...
Float so low GRAY wll run hard with BUY pressure...
GLTA
Watch for results of GRAY speaking at Cantor Fitzgerald Global Healthcare Conference 9/28.
Imagine the Big Pharma eyes & interest for GRAY's confirmed results 9/28 for "full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD)" along with GRAY's $78.2m on hand at this conference. Big Pharma interest for sure...
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET / 8:20 a.m. PT. Dr. Guerard will provide a corporate update, including a full analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg.
A live webcast of the presentation will be available in the Investors and Media section of the company's website at https://investors.graybug.vision/news-events/events-presentations, with a replay available shortly after the live event.
GLTA
...
.....
GRAY 9/28: Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
September 28 2021 - 07:30AM.
"Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally.
The ALTISSIMO trial was a masked and controlled Phase 2b dose-ranging study of two doses of GB-102, 1mg and 2mg, with a single control arm of patients on 2mg aflibercept, conducted across 33 study sites in the United States. The primary endpoint was median time to first supportive therapy with a vascular endothelial growth factor (VEGF) inhibitor, and secondary endpoints were safety and pharmacodynamics, measured as mean change in best-corrected visual acuity (BCVA) and mean change in central subfield thickness (CST) of the retina. As previously reported, the development of GB-102 2mg was terminated in 2020 following an interim safety analysis, and ALTISSIMO was not powered to assess non-inferiority to aflibercept.
ALTISSIMO comprised two phases, the first of which was a 12-month treatment phase, or Core Study, in which GB-102 patients were dosed at Day 1 and Month 6, while a control arm received aflibercept every other month. The second phase of ALTISSIMO was a six-month extended observation phase, or Extension Study, in which patients were monitored without additional treatment to determine the duration of effect measured from their last treatment during the Core Study. Participation in the Extension Study was voluntary, but only patients who completed all study visits, and did not require supportive therapy at their Month 12 visit during the Core Study, were eligible. 58% of the patients who completed the Core Study were eligible and agreed to enter the Extension Study, with 11 patients participating in the GB-102 1mg arm.
By its design, patients could not achieve longer than a six-month duration during the Core Study. The Extension Study provided up to an additional six months for patients to demonstrate longer duration, which resulted in 55% of GB-102 1mg patients experiencing a treatment duration of 12 months or longer, while maintaining visual acuity and central retinal thickness. This is the longest duration ever achieved with an intravitreal injection in a randomized, masked, and controlled clinical trial in wet AMD. In addition, the injection burden was reduced by 73% on an annualized basis for those GB-102 1mg patients who participated in the six-month Extension Study.
As in the Core Study, GB-102 1mg continued to be well-tolerated and maintained a favorable safety profile during the Extension Study. No drug-related adverse events or vision-threatening inflammation were reported.
“The Extension Study gave us our first opportunity to see duration beyond six months in a masked and controlled trial, and we are very excited that the majority of patients volunteering for extended observation achieved a treatment duration of 12 months or longer,” said Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug. “Furthermore, the significant reduction in injection burden continued throughout the Extension Study and showed that GB-102 1mg has the potential to significantly improve compliance compared to the current standard of care,” Dr. Zamiri concluded.
Graybug continues to optimize its technology platform and is developing additional formulations that have the potential to preserve the durability of GB-102 1mg microparticles while minimizing the risk of dispersion. These new and enhanced formulations, including injectable implants, may also simplify the drug reconstitution process and the injection technique, both of which are sources of variability in clinical outcomes. These innovations have already been incorporated into the development programs of both GB-102 and GB-401. Graybug anticipates that its GB-401 implant program for glaucoma will enter a Phase 1 trial in the second half of 2022. Given the 12-month or longer duration observed with GB-102 in the ALTISSIMO 18-month trial, Graybug decided to stop the further development of GB-103, which was designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection.
“We are encouraged by the Extension Study data that indicate a class-leading durability of GB-102 1mg of 12 months, or longer,” said Fred Guerard, PharmD, Chief Executive Officer, Graybug Vision. “These data further support the significant commercial opportunity that GB-102 1mg could represent. Our search for a partner to fund the further clinical development of GB-102 is ongoing.”
GLTA
...
...
GRAY what’s UP after-hours boom???
yup!! still holding here for $5+ break
Great to see GRAY 7%+ on such a market RED day...
Hopefully news/update coming...
GRAY float so small we can fly with some BUY pressure !!!
GLTA
...
...
No position currently...will watch for another entry...
GRAY looking great again today !
Back to the $15s as lows soon...
GLTA
Yes Indeed...Psar flipped to a Bullish Buy Position off the $3.50 range bottom...
GRAY with some pre-market Bid-slappin UP...
Over $4 already...
It's about TIME to return to previous $15 lows as was...
GLTA
>>>
...
Bidding $3/$3.50…it will find its bottom and reverse …I am patient…
would like to see some bullish reversal from here
this stock got destroyed. first found it at $4.50 ish
Been a great trader for me…Nice Grabs in this range…
would be nice. snagged some $3.88s and $3.89s
Bottoming out here
GRAY $78.2m onhand + Q2 EPS $(0.36) =94.7% improvement YoY!!!
8/11 filing: "As of June 30, 2021, the company's cash and cash equivalents, and short-term and long-term investments totaled $78.2 million. Management believes the company's current cash and investments are sufficient to support its currently planned operations into 2023."
GLTA
...
...
...
GRAY only 28k traded today.
Somethings UP
It looks that the last 7-days of the breeding are finally stopped. Hope today is a turning point and GRAY starts to move to the July 16, 2021 CALL $7.50 and higher.
I agree with you. Look at CARV today by short squeezing.
GRAY moves crazy after hours.
We have such a small float it takes light pressure to ramp UP !
The SHORTs are controlling the price pretty well. It is interesting to see what will happen tomorrow.
It looks that your chart predicts pretty accurately. Congrats!
Investors (both LONGs and SHORTs) in GRAY need to pay close attention to this stock because the Jul 16, 2021 $7.50 Call has some high implied volatility of equity options, which may show how much movement the market is expecting in the future. I wonder whether the Options Market will predict a spike in GRAY in about two weeks.
GRAY...$4.81...Bidding the lower band range for another entry...
Chart...https://schrts.co/gCUxTdam ...
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
182
|
Created
|
03/18/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |